All MASAC Recommendations

Below are treatment recommendations from NHF's Medical and Scientific Advisory Council (MASAC).

STANDARDS AND CRITERIA
MASAC Document #	Board Approved Date	Title
132	3/24/2002	Standards and Criteria for the Care of Persons With Congenital Bleeding Disorders
TREATMENT RECOMMENDATIONS
179	11/04/2007	MASAC Recommendation Concerning Prophylaxis
195	06/26/2010	MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders
183	11/16/2008	MASAC STATEMENT REGARDING USE OF HERBAL OR HOMEOPATHIC PRODUCTS TO TREAT VON WILLEBRAND DISEASE
MANAGEMENT ISSUES
115	6/9/2001	MASAC Recommendations Regarding Central Venous Access Devices Including Ports and Passports
128	11/17/2001	MASAC Recommendations for Hepatitis A and B Immunization of Individuals with Bleeding Disorders
147	11/9/2003	TRANSITION GUIDELINES For People with Bleeding Disorders
162	6/4/2005	MASAC Recommendations on Use of COX-2 Inhibitors in Persons with Bleeding Disorders
CLOTTING FACTOR PRODUCTS
31	3/30/1993	MASAC Statement on Phase IV Post Licensing Studies
37	8/2/1994	MASAC Recommendation Concerning Parvovirus Transmission by Clotting Factor Concentrates
73	11/2/1997	Recommendations Regarding Blood Safety Policies
99	6/10/2000	MASAC Resolution on Creutzfeldt-Jakob Disease, new variant CJD, and Plasma-Derived Coagulation Products
139	3/8/2003	MASAC RECOMMENDATIONS ON THE IQPP AND QSEAL PROGRAMS OF THE PLASMA PROTEIN THERAPEUTICS ASSOCIATION
140	3/8/2003	MASAC Recommendation on Reporting of Possible West Nile Virus Cases
157	11/7/2004	MASAC Resolution on the Thrombogenicity of Bypassing Agents for Management of Hemophilia Complicated by Inhibitors
158	11/7/2004	MASAC Recommendations Regarding Exposure to Blood Product Derivatives and Potential Risk of vCJD.
EMERGENCY CARE
113	3/4/2001	MASAC Recommendations on Improved Access to Emergency Medical Care for Persons with Inherited Bleeding Disorders
129	11/17/2001	MASAC Resolution Regarding Emergency Supply of Factor Concentrate
175	10/15/2006	GUIDELINES FOR EMERGENCY DEPARTMENT MANAGEMENT OF INDIVIDUALS WITH HEMOPHILIA
INFECTIOUS DISEASE COMPLICATIONS
90	10/25/1998	MASAC Revised Recommendation Regarding Treatment of HCV in HIV Coinfected Individuals with Hemophilia and Other Inherited Bleeding Disorders
93	6/26/1999	MASAC Statement on Pregnancy Options for HIV-Discordant Couples
98	6/10/2000	MASAC Recommendations on Liver Biopsy in Individuals with Hemophilia
108	11/12/2000	MASAC Recommendation Regarding Treatment of AIDS Wasting
109	3/4/2001	MASAC Resolution Concerning Participation in AIDS Clinical Trials by HIV-Infected Persons with Bleeding Disorders
110	3/4/2001	MASAC Recommendation Concerning CMV Screening of Blood Products for Use in HIV-Positive Individuals with Hemophilia
119	6/9/2001	MASAC Recommendation Regarding Post HIV-Exposure Chemoprophylaxis (see also #123)
121	11/17/2001	MASAC Recommendations for Immunization of HIV-Infected Individuals
123	11/17/2001	MASAC Recommendations Regarding Hepatitis B, Hepatitis C and HIV Postexposure Chemoprophylaxis
154	11/9/2003	MASAC RECOMMENDATIONS REGARDING THE USE OF ANTIRETROVIRAL THERAPY IN THE TREATMENT OF HIV INFECTION (Revised November 2003)
193	11/16/2009	MASAC Recommendation Regarding Availability of HCV Treatment Trials
ORTHOPEDICS AND PHYSICAL THERAPY
102	11/12/2000	MASAC Recommendation Regarding the Need for Collaborative Effort to Collect Data Regarding Interventions to Prevent Joint Damage Secondary to Hemophilia
105	11/12/2000	MASAC Recommendation Regarding Prevention of Cryptosporidiosis in and the Use of Therapeutic Pools by HIV-Infected Persons
130	3/24/2002	MASAC Recommendation Regarding the Use of Therapeutic Ultrasound to Aid in Blood Resorption
194	06/26/2010	MASAC Recommendations Regarding Radionuclide Synovectomy
POLICY
28	11/22/1992	MASAC Statement on Testimony Provided by Physicians and/or Others Associated with the National Hemophilia Foundation
40	8/2/1994	MASAC Resolution on Home Care Delivery Systems
73	11/2/1997	MASAC RECOMMENDATIONS REGARDING BLOOD SAFETY POLICIES
94	12/21/1999	Resolution Regarding Consumer Participation in the National Notification System
101	6/10/2000	MASAC Recommendation Regarding Reimbursement for Treatment of Acquired Hemophilia
111	3/4/2001	MASAC Resolution Concerning the Development of Comprehensive Outcome Measures
136	11/2/2002	MASAC STANDARD ON DISCLOSING CONFLICTS OF INTEREST FOR INDIVIDUALS CONDUCTING CLINICAL RESEARCH ON BLEEDING AND CLOTTING DISORDERS
138	11/2/2002	MASAC RESOLUTION ON REIMBURSEMENT FOR INDIVIDUALS RESUMING USE OF RECOMBINANT FACTOR VIII CONCENTRATE
140	3/8/2003	MASAC RESOLUTION ON REPORTING OF POSSIBLE WEST NILE VIRUS CASES
174	10/15/2006	MASAC RECOMMENDATIONS REGARDING RARE COAGULATION FACTOR DISORDERS
145	10/19/2003	MASAC RECOMMENDATION ON FUNDING OF THE OFFICE OF CELLULAR AND GENE THERAPIES
146	10/19/2003	MASAC Recommendation Regarding Medicaid Inpatient Clotting Factor Replacement Therapy Reimbursement for Hemophilia
148	11/9/2003	MASAC Resolution on NHF Educational Program for Fellows
149	11/9/2003	MASAC Recommendation on the World Health Organization Essential Drug List
152	11/9/2003	MASAC Recommendations Regarding the Inclusion of Thrombophilia in NHF Research and Educational Efforts
153	11/9/2003	MASAC Recommendation Concerning Reimbursement for Recombinant Clotting Factor Concentrates
159	3/12/2005	MASAC Recommendation Regarding Factor Concentrate Prescriptions and Formulary Development and Restrictions
188	11/16/2008	MASAC Recommendations Regarding Standards of Service for Pharmacy Providers of Clotting Factor Concentrates for Home Use to Patients with Bleeding Disorders
184	11/16/2008	MASAC CONSENSUS STATEMENT REGARDING THE USE OF FRESH FROZEN PLASMA FOR THE IMMEDIATE REVERSAL OF THE ANTICOAGULANT EFFECTS AND/OR BLEEDING COMPLICATIONS ASSOCIATED WITH ORAL VITAMIN K ANTAGONISTS
RESEARCH
91	2/28/1999	MASAC Recommendation Regarding Risk of Germline Transmission in Gene Therapy Trials for Hemophilia
96	12/21/1999	MASAC Resolution on Genotyping of Persons with Inherited Bleeding Disorders
111	3/4/2001	MASAC Resolution Concerning the Development of Comprehesive Outcome Measures
127	11/17/2001	MASAC Recommendation Regarding Risks of Gene Therapy Trials for Hemophilia
136	11/2/2002	MASAC STANDARD ON DISCLOSING CONFLICTS OF INTEREST FOR INDIVIDUALS CONDUCTING CLINICAL RESEARCH ON BLEEDING AND CLOTTING DISORDERS
137	11/2/2002	MASAC RECOMMENDATIONS FOR CONDUCTING GENE TRANSFER CLINICAL TRIALS IN PERSONS WITH BLEEDING DISORDERS (Revised November 2002)
144	10/19/2003	MASAC STATEMENT ON THE ROLE AND RESPONSIBILITIES OF THE PRINCIPAL INVESTIGATOR IN BLEEDING DISORDER CLINICAL TRIALS
160	3/12/2005	MASAC Recommendation on the Need for Long-Term Follow-Up of Hemophiliac Dogs in Gene Transfer Studies
161	6/4/2005	MASAC Resolution on Stem Cell Research for Potential Cure of Bleeding Disorders
WOMEN AND BLEEDING DISORDERS
77	2/21/1998	Recommendations Regarding Neonatal Intracranial Hemorrhage and Postpartum Hemorrhage
93	6/26/1999	MASAC Statement on Pregnancy Options for HIV-Discordant Couples
119	6/9/2001	MASAC Recommendation Regarding Post HIV-Exposure Chemoprophylaxis
122	11/17/2001	MASAC Recommendations Concerning the Use of Antiretroviral Drugs During Pregnancy to Prevent Transmission of HIV to the Infant
150	11/9/2003	MASAC Recommendations on the Use of Blood Products during Pregnancy and Testing for Parvovirus B19
197	06/26/10	Recommendations Regarding Girls and Women with Inherited Bleeding Disorders
196	06/26/10	MASAC Resolution Regarding the Treatment of von Willebrand Disease
180	6/15/08	MASAC Endorsement of the NHLBI Consensus Guidelines on the Diagnosis and Treatment of Von Willibrand Disease